Newly Diagnosed Acute Myeloid Leukemia
Conditions
Interventions
treatment group:amifostine+IA
control:IA
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 18 Years and older; 2. Both two genders; 3. Newly diagnosed patient with acute myeloid leukemia (AML) types M0-M2, M4-M7; 4. Histologically proven by bone marrow aspirate and biopsy requirement may be waived for patients with overt leukemia in the peripheral blood; 5. Evaluable disease; PATIENT CHARACTERISTICS: Age: 18 and over; Performance status: Karnofsky60-100%ECOG 0-2; Life expectancy at least 3 months; Hematopoietic not specified; Hepatic SGOT/SGPT no greater than 2.5 times upper limit of normal; Renal creatinine no greater than 2.0 mg/dL; Cardiovascular ejection fraction at least 50%; Must be able to stop taking antihypertensive medication 24 hours prior to cytarabine administration; Other: (1) No preexisting severe organ dysfunction; (2) No history of underlying medical or psychiatric illness that may impair the patient's ability to participate in the study; (3) Not pregnant or nursing; (4) Effective contraception required of fertile patients; PRIOR CONCURRENT THERAPY: Biologic therapy not specified; Chemotherapy: See Disease Characteristics; No prior cytotoxic therapy for AML; No prior amifostine; At least 1 month since chemotherapy. Endocrine therapy not specified.
Exclusion criteria
Exclusion criteria: not applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| nonhematologic side effects; | — |
Secondary
| Measure | Time frame |
|---|---|
| hypotension; | — |
Contacts
Public ContactJin LU
Outcome results
None listed